Dynamic changes in lung MicroRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 4, 2010, Pages 716-723

  Caruso, Paola ^a   MacLean, Margaret R ^b   Khanin, Raya ^c   McClure, John ^a   Soon, Elaine ^d   Southgate, Mark ^d   MacDonald, Robert A ^a   Greig, Jenny A ^a   Robertson, Keith E ^a   Masson, Rachel ^a   Denby, Laura ^a   Dempsie, Yvonne ^b   Long, Lu ^d   Morrell, Nicholas W ^d   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Gene regulation; Pulmonary hypertension; Small RNA molecules

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; MICRORNA; MONOCROTALINE; RNA; TRANSFORMING GROWTH FACTOR BETA1; RIBONUCLEASE III;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MALE; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SERUM; ANIMAL; ANOXIA; BLOOD; CELL CULTURE; CELL HYPOXIA; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DISEASE MODEL; DNA MICROARRAY; FIBROBLAST; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LUNG; METABOLISM; METHODOLOGY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TIME; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ANIMALS; ANOXIA; CELL HYPOXIA; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICRORNAS; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASE III; TIME FACTORS;

EID: 77950878463     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.202028     Document Type: Article

References (34)

1. Rich S, Dantzker D, Ayres S, Bergofsky E, Brundage B, Detre K, Fishman A, Goldring R, Groves B, Koerner S. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107: 216-223. (Pubitemid 17137857)
2. International PPH Consortium; Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-/3 receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
3. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Halme M, Raisanen-Sokolowski A, Laitinen T, Morrell NW, Trembath RC. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary hae-morrhagic telangiectasia. J Med Genet. 2003;40:865-871.
4. Dempsie Y, Morecroft I, Welsh D, MacRitchie N, Herold N, Loughlin L, Nilsen M, Peacock A, Harmar A, Bader M, MacLean M. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation. 2008;117:2928-2937.
5. Lawrie A, Spiekerkoetter E, Martinez E, Ambartsumian N, Sheward W, MacLean M, Harmar A, Schmidt A, Lukanidin E, Rabinovitch M. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005;97: 227-235.
6. Long L, MacLean M, Jeffery T, Morecroft I, Yang X, Southwood N, James V, Trembath R, Morrell N. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res. 2006;98: 818-827.
7. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005;33:2697-2706.
8. Lee Y, Han J, Yeom KH, Jin H, Kim VN. Drosha in primary microRNA processing. Cold Spring Harb Symp Quant Biol. 2006;71:51-57.
9. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res. 2006;34:4622-4629.
10. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004;303:95-98.
11. MacRae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, Adams PD, Doudna JA. Structural basis for double-stranded RNA processor by Dicer. Science. 2006;311:195-198.
12. Hammell CM. The microRNA-argonaute complex. RNA Biol. 2008;5: 123-127.
13. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58-63.
14. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 2008;105:13556-13561.
15. Ambs S, Prueitt R, Ming Y, Hudson R, Howe T, Petrocca F, Wallace T, Liu C-G, Volinia S, Calin G, Yfantis H, Stephens R, Croce C. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68: 6162-6170.
16. Yang H, Kong W, He L, Zhao J-J, O'Donnell D, Wang J, Wenham R, Coppola D, Kruk P, Nicosia S, Cheng J. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425-433.
17. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116: 258-267.
18. Mann DL. MicroRNAs and the failing heart. N Engl J Med. 2007;356: 2644-2645.
19. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol. 2007;170:1831-1840.
20. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 2009;23:806-812.
21. Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004;573:83-92.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JRSS-B. 1995;57: 289-399.
23. Wang Y, Weng T, Gou D, Chen Z, Chintagari NR, Liu L. Identification of rat lung-specific microRNAs by micoRNA microarray: valuable discoveries for the facilitation of lung research. BMC Genomics. 2007;8:29.
24. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009;104:1184-1191.
25. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-/3 signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119:566-576.
26. Gal H, Pandi G, Kanner A, Ram Z, Lithwick-Yanai G, Amariglio N, Rechavi G, Givol D. MIR-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem Biophys Res Commun. 2008; 376:86-90.
27. Grimson A, Srivastava M, Fahey B, Woodcroft BJ, Chiang HR, King N, Degnan BM, Rokhsar DS, Bartel DP. Early origins and evolution of microRNAs and Piwi-interacting RNAs in animals. Nature. 2008;455: 1193-1197.
28. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J. 1995;8: 2129-2138.
29. Voelkel N, Tuder R. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest. 2000;106:733-738.
30. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol. 1991;71:2483-2492.
31. Laudi S, Steudel W, Jonscher K, Schoning W, Schniedewind B, Kaisers U, Christians U, Trump S. Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics. 2007;7: 2469-2478.
32. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean D, Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579-1588.
33. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454:56-61.
34. Baek D, VillAen J, Shin C, Camargo F, Gygi S, Bartel D. The impact of microRNAs on protein output. Nature. 2008;455:64-71.